Evidence map›Paper›PMID 31692513›Full record

ArticleCancer management and research2019

Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma.

Francesca Galuppini, Matteo Fassan, Loris Bertazza, Susi Barollo, Luciano Cascione, Sara Watutantrige-Fernando, Vanni Lazzarin, Paolo Simonato, Federica Vianello, Massimo Rugge and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Francesca GaluppiniPathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Matteo FassanPathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Loris BertazzaEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Susi BarolloEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Luciano CascioneUniversità Della Svizzera Italiana, Institute of Oncology Research and Swiss Institute of Bioinformatics , Bellinzona 6500, Switzerland.
Sara Watutantrige-FernandoDepartment of Radiotherapy, Istituto Oncologico del Veneto, Padova 35128, Italy.
Vanni LazzarinPathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Paolo SimonatoPathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Federica VianelloDepartment of Radiotherapy, Istituto Oncologico del Veneto, Padova 35128, Italy.
Massimo RuggePathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Caterina MianEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
Gianmaria PennelliPathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy.
University of Padua · ITIstituto Oncologico Veneto · ITSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe primary goal of papillary thyroid cancer (PTC) management was to stratify patients at pre- and post-surgical level to identify the small proportion of cases with potentially aggressive disease. PURPOSE: The aim of our study is to evaluate the possible role of programmed cell death 4 (PDCD4) and BRAF status as prognostic markers in PTC. PATIENTS AND

methodsWe investigate programmed cell death 4 (PDCD4) immunohistochemical expression in 125 consecutive PTCs with median follow-up of 75.3 months (range, 15-98 months) to verify the possible correlation between BRAF status and correlate the classical clinicopathological prognostic factors and PTC outcome with PDCD4 expression. To further support the data, miR-21 expression was tested (by quantitative real-time PCR and in situ hybridization) in a different series of 30 cases (15 PTCs BRAFwt and 15 PTCs BRAFV600E). Moreover, we validated our results using TGCA thyroid carcinoma dataset.

resultsWe found that 59.8% of the patients showed low-grade PDCD4 nuclear expression and low-grade expression correlated with BRAF V600E. Compared with BRAF 15 wild-type tissue samples, a significant miR-21 up-regulation was associated with BRAF V600E mutations. Low-grade PDCD4 resulted, and was associated with aggressive histological variants, higher cancer size, extra-thyroidal extension, multifocality, lymph-node metastasis and lymph nodal ratio at the diagnosis. Concerning the outcome, the low-grade PDCD4 expression correlated at univariate and multivariate analysis, with lower levels of recurrence-free survival rate (RFS) and with poor outcome. Moreover, there was significant association between BRAF V600E patients with PDCD4 nuclear loss and lower RFS, whilet here was significant association between BRAF wild-type patients with PDCD4 nuclear expression and better outcome.

conclusionThese results showed that PDCD4 could predict PTC outcome and that the sum of PDCD4 and BRAF alterations increases the prognostic power of BRAF mutation alone.

Indexed as

BRAFoutcomepapillary thyroid cancerPDCD4

Identifiers

PMID31692513
PMCPMC6708393
OpenAlexW2969522485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.